The use of a 90-day extended duration vaginal ring containing 100 or 200 mg of the antiretroviral drug dapivirine appeared safe, effective, and acceptable among HIV-negative women, according to results of a phase I trial presented at CROI 2021.
The oral antiviral drug molnupiravir, given for 5 days, eliminated SARS-CoV-2 in the nasopharynx of patients with COVID-19, interim results of a phase IIa study have shown, boosting hopes for its potential use in the outpatient setting.
A minimal monitoring (MINMON) approach to treatment of hepatitis C virus (HCV) infection with sofosbuvir/velpatasvir appeared to render an acceptable sustained virological response (SVR), according to results of the phase IV ACTG* A5360 trial.
Treatment with intranasal insulin (INI) improves the performance of virally suppressed people with HIV (VS-PWH) on neuropsychological tests related to memory and attention, according to a study presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2021.
For HIV patients treated with antiretroviral therapy (ART), higher
levels of inflammatory biomarkers help predict non-AIDS cardiovascular (CV) events
more strongly in women than men, according to a study.
Improvements in depression symptoms remain stable at 6 years in individuals who maintain viral suppression after antiretroviral therapy (ART) during acute HIV-1 infection (AHI), according to a Thai study presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2021.
Treatment-naïve individuals with HIV continued to benefit from the dolutegravir-lamivudine regimen for nearly 3 years regardless of baseline disease characteristics and demographics, as shown by its noninferiority to dolutegravir plus tenofovir and emtricitabine observed in the subgroup analyses of the GEMINI trials presented at CROI 2021.
Even without a history of dyslipidaemia, hypertension, or diabetes, people with HIV (PWH) suffer from a nearly 30-percent higher risk of cardiovascular disease (CVD), according to a study presented at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021).
A 4-month regimen containing the combination of rifapentine (RPT) and moxifloxacin (MOX) can effectively treat tuberculosis (TB) in HIV-positive patients, performing just as well as the 6-month standard of care, according to a subgroup analysis of the landmark phase III S31/A5349 trial.
Sex appears to have a strong influence on many discrete pathways of inflammation that independently predict cardiovascular disease (CVD) and venous thromboembolism (VTE) events in patients with HIV on antiretroviral therapy (ART), according to a study presented at the Conference on Retroviruses and Opportunistic Infections 2021.
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.